US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted A61PA61P35/00A61P43/00
Quick answer
US patent 11008622 (Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof) held by Wellmarker Bio Co., LTD. expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Wellmarker Bio Co., LTD.
- Grant date
- Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61P, A61P35/00, A61P43/00